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Multiple sclerosis (MS) is a central nervous system disease in which activated autoreactive T-cells
invade the blood brain barrier and initiate an inﬂammatory response that leads to myelin destruction and
axonal loss. The etiology of MS, as well as the mechanisms associated with its unexpected onset, the
unpredictable clinical course spanning decades, and the different rates of progression leading to
disability over time, remains an enigma. We have applied gene expression microarrays technology in
peripheral blood mononuclear cells (PBMC) to better understand MS pathogenesis and better target
treatment approaches. A signature of 535 genes were found to distinguish immunomodulatory
treatment effects between 13 treated and 13 untreated MS patients. In addition, the expression pattern of
1109 gene transcripts that were previously reported to signiﬁcantly differentiate between MS patients
and healthy subjects were further analyzed to study the effect of cytokine-related pathways on disease
pathogenesis. When relative gene expression for 26 MS patients was compared to 18 healthy controls,
30 genes related to various cytokine-associated pathways were identiﬁed. These genes belong to a
variety of families such as interleukins, small inducible cytokine subfamily and tumor necrosis
factor ligand and receptor. Further analysis disclosed seven cytokine-associated genes within the
immunomodulatory treatment signature, and two cytokine-associated genes SCYA4 (small inducible
cytokine A4) and FCAR (Fc fragment of IgA, CD89) that were common to both the MS gene
expression signature and the immunomodulatory treatment gene expression signature. Our results
indicate that cytokine-associated genes are involved in various pathogenic pathways in MS and also
related to immunomodulatory treatment effects.
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INTRODUCTION
Multiple sclerosis(MS)isacentralnervoussystemdisease
with an unpredictable clinical course and outcome. A
varietyof genetic, immunologic and environmental factors
have been implicated in triggering the onset and
progression of the disease. Genetic background may play
a role in disease pathogenesis as MS is more common in
Caucasians and disease frequency increases with distance
from the Equator in both hemispheres (Kenealy et al.,
2003). Pathologically, the disease is characterized by
perivascular inﬁltration of monocytes and lymphocytes
mainly CD4 cells within the brain and spinal cord that lead
to myelin destruction (Prat and Martin, 2002). Peripheral
blood mononuclear cells (PBMC) are involved in
the pathogenesis of the disease and induce active
demyelination. Autoreactive activated T-cells invade
the blood brain barrier and initiate an inﬂammatory
response that leads to myelin destruction and signiﬁcant
neurological disability. However, the etiology of MS, as
well as the mechanisms associated with its unexpected
onset, the unpredictable clinical course spanning decades,
and the different rates of progression leading to disability
over time, all still remain enigmas. New approaches are
needed to better understand MS pathogenesis and in order
to better target treatment approaches to identify patients
with poor prognosis. Gene expression microarray techno-
logy is a new tool for comprehensively detecting and
quantifying tens and thousands of gene transcripts
simultaneously (Kolbert et al.,2 0 0 3 ) .T h i sp a r a l l e l
quantiﬁcation of large number of messenger RNA
transcripts provides detailed insight into cellular processes
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new understanding of signaling networks that operate
within cells or tissues and of the molecular processes
involved(Watsonetal.,1998).SpeciﬁcallyinMS,whichis
considered a multi-factorial and heterogeneous disease,
research interest is not aimed at ﬁnding a single change in
gene expression that might be the key to different disease
phenotypes, but rather at evaluating overall patterns of
gene expression in order to understand the architecture of
genetic regulatory networks involved in the disease
(Baranzini and Hauser, 2002). Thus, instead of looking
foraneedleinahaystack,microarraystechnologyallowsa
global approach that could ultimately lead to identiﬁcation
of the transcription-control mechanisms operating the
pathological disease processes.
In a recent study we have reported the identiﬁcation of a
statistically signiﬁcant transcriptional signature of 1109
genes expressed in PBMC from 26 MS patients using
oligonucleotide microarrays (Achiron et al., 2004). The
MS signature contained genes involved in T-cell
activation and expansion, inﬂammation and apoptosis,
and was irrespective to the disease activation state or
immunomodulatory treatment. Another transcriptional
signature consisting of 721 genes involved in cellular
recruitment, epitope spreading, and escape from
regulatory immune surveillance, identiﬁed MS patients
in acute relapse compared to remission.
In the current study, we studied the effect of
immunomodulatory treatment on MS gene expression
signature, and further evaluated the autoimmune mecha-
nismsinvolvedbyspeciﬁcallyassessingcytokine-associated
genes expression.
Cytokines have crucial functions in the development,
differentiation and regulation of immune cells. As a result,
dysregulation of cytokine production or action is thought
to have a central role in the development of autoimmunity
and autoimmune diseases such as MS. Moreover, the fact
that the new immunomodulatory drugs (i.e. beta-
interferons, glatiramer acetate and intravenous imuno-
globulins) used for the treatment of MS, are though to
affect and modulate the autoreactive immune response
through the cytokine pathways (Dhib-Jalbut, 2002),
prompt us to investigate whether speciﬁc expression of
gene transcripts is associated with alteration of cytokine
levels and immunomodulatory treatment effects.
METHODS
Patients
Twenty-six patients with deﬁnite MS and a relapsing-
remitting disease course were included in the PBMC gene
expression study and participated in the cytokine
expression and immunomodulatory treatment effect
analyses. The clinical and demographic variables of the
study patients were previously reported (Achiron et al.,
2004). Thirteen patients were on immunomodulatory
treatments (interferon beta-1a, interferon beta-1b,
glatiramer acetate and IVIg) for at least 3 months prior
to gene expression study, and 13 patients were naı ¨ve to
immunomodulatory treatment. All patients had peripheral
blood counts within the normal range. The Sheba Medical
Center Institutional Review Board approved the study,
and all patients gave written informed consent for
participation.
RNA Isolation and Microarray Expression Proﬁling
PBMC were separated on ﬁcol hypaque gradient, total
RNA was puriﬁed, labeled, hybridized to a 12,000
Genechip array (U95Av2) and scanned (Hewlett Packard,
GeneArray-TM scanner G2500A) according to the
manufacturer’s protocol (Affymetrix Inc, Santa Clara,
CA). MAS5 software (Affymetrix Inc.) was used to
analyze the scanned arrays. All data were normalized by
dChip software (Li and Wong, 2001). Probes that did not
have an expression value of 100 in at least one of the
arrays were ﬁltered. The hybridization of the arrays was
done in eight batches. A Unigene cluster was assigned to
each of the Affymetrix probe sets to obtain gene speciﬁc
annotation.
Statistical Analysis
Statistical analysis was performed using the ScoreGenes
software tools (http://compbio.cs.huji.ac.il/scoregenes/).
The gene expression proﬁle of each patient was normal-
ized to the median gene expression proﬁle for the entire
sample as previously described (Achiron et al., 2004). The
data were analyzed by the classic parametric t-test, and the
non-parametric tests the threshold number of misclassi-
ﬁcations (TNoM) method and the Info score to identify
differences in mean gene expression levels between
comparison groups (Kaminski and Friedman, 2002). Fold
change was calculated for each gene in the samples
against the geometric mean of controls and log (base 2)
transformed. The most informative differentially
expressed genes were deﬁned as those that pass 95%
conﬁdence interval on all three statistical tests (t-test,
TNoM and Info).
Evaluation of immunomodulatory treatment effect by
gene expression to assess speciﬁc gene transcripts
associated with treatment was performed using a 12,000
Genechip array. The 1109 most informative genes that
differentiated MS patients from healthy subjects (Achiron
et al., 2004), served to investigate a speciﬁc autoimmune
signature associated with cytokine-related gene
expression. To control for artifacts of batches we ﬁtted a
multiple effect model for each gene, where, we modeled
the log-ratio measurement as a sum of contributions of
(a) batch, (b) subject state (control, MS), (c) treatment and
(d) array speciﬁc noise. We ﬁtted the model to minimize
the least sum of squares of the errors, and created a
cleaned log-ratio ﬁle by removing from each log-ratio the
associated batch effect parameter. Spotﬁre DecisionCite
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RESULTS
Gene Expression Patterns Identify
Immunomodulatory Treatment Effects in MS
Gene expression patterns between treated and untreated
MS patients differed by a set of 535 genes (represented by
539 probes). Although patients were on various immuno-
modulatory treatments for different periods of time, these
535 genes were differentially expressed ðp , 0:05 in all
three statistical scoring tests) between treated and
untreated MS patients. Of these, only 57 were among
the 1109 genes within the MS expression signature, and 34
were among the 721 genes related to the disease phase
transcriptional signature. Three-dimensional Scatter Plot
of these genes (Fig. 1A) clearly demonstrates a difference
between treated and untreated MS patients. An example of
signiﬁcantly differentiating genes with a differential
behavioral pattern between treated and untreated patients
is shown in relapse (Fig. 1B) and in remission (Fig. 1C).
Cytokine-related Gene Transcripts in MS
Analysis of the expression pattern of the 1109 gene
transcripts that signiﬁcantly differentiate between MS
patients and healthy subjects to study the cytokine-related
gene transcripts demonstrated 30 genes that passed 95%
FDR and exhibited ðp , 0:05Þ in all three statistical
scores, (Table I). Most of thesegenes belong to avariety of
cytokine families such as TNF ligand and its receptor,
interleukins and small inducible cytokine subfamily.
There was no effect of immunomodulatory treatments on
the cytokine-related genes within the MS signature, as
analysis of the non-treated MS patients resulted in the
same level of expression of these genes.
Cytokine-related Gene Transcripts Associated with
Immunomodulatory treatment in MS
Further analysis of the 535 treatment-related genes
disclosed seven cytokine-related genes within the MS
immunomodulatory treatment signature, (Table II). Two
genes small inducible cytokine A4 (SCYA4) and Fc
fragment of IgA, CD89 (FCAR) were common to the
cytokine-related pathways within both the MS signature
and the immunomodulatory treatment signature.
DISCUSSION
In the current study our ﬁndings demonstrate that
immunomodulatory treatment transcriptional signature
can be identiﬁed by microarray analysis. As the MS
patients included in the study were treated with various
immunomodulatory treatments and also differed in
relation to treatment duration, the possibility to deﬁne
speciﬁc drug effects was limited. Even though, we
identiﬁed speciﬁc treatment related gene pattern that
differentiated between treated and untreated patients.
Although currently the precise mechanisms of action of
immunomodulatory treatments in MS are not fully
understood, it is conceivable that in the future, assessment
of speciﬁc pathways related to treatment effects could be
analyzed by gene microarray technology. Identiﬁcation of
these pathways will serve to predict patients that are
responders or non-responders to immunomodulatory
interventions even before treatment is initiated.
The second question evaluated in the current study was
related to the role of cytokine pathways in MS. Numerous
studies have addressed this question, often with conﬂicting
results; elevated, normal and decreased levels of almost all
cytokines have been reported (Martino et al., 2000; Ozenci
etal.,2002).Inthecurrentstudywedemonstratedwithinthe
MSspeciﬁcgeneexpressionsignature,severaldistinguished
groups of cytokine related genes responsible for migration
ofinﬂammatorycellsandT-cellmediatedimmuneresponse
regulation. These include the chemokine group ligands
CXCL, interleukins and their receptors, TNF family and
small inducible cytokine family. These genes participate in
various pathogenic pathways involved in MS including
inﬂammatory cell migration (CXCL1, CXCL2, CXCL3,
IL8,SCYA2,SCYA4,SCYA20,SCYE1),T-cell activation
and expansion (NFATC3, IL15, IL2RB), apoptosis
(TNFRSF4, TNF, TNFSF6, MAP2K3), demyelination
(SCYA20, IL1b, IL1R1) and immune regulation (IL6,
CEBPB). We therefore, suggest the following sequence of
cytokine-related events to play a role in MS pathogenesis
(Fig. 2).
Inﬂammatory Cell Migration
MS is considered as a T-cell-mediated inﬂammatory
demyelinating disease in which the immune system is
tricked to ﬁrst see central nervous system myelin as foreign
andthentodestroyit(Trapp,2004).Althoughthetriggerthat
induces T-cell-mediated myelin destruction has not yet been
identiﬁed, we suggest that once the autoimmune process has
beeninitiateditinvolvesinﬂammatorycellmigrationintothe
central nervous system. The chemokine group ligands
CXCL1 (GRO1), CXCL2 (GRO2) and CXCL3 (GRO3) are
ligands to the CXC chemokine subfamily. CXCL1 is
amitogenicfactorinvolvedininﬂammatoryprocesses,witha
chemotacticactivityforneutrophils,andisknowntoregulate
embryonic oligodendrocyte precursor migration (Tsai et al.,
2002). CXCL2 is produced by activated monocytes and
neutrophils,expressedatsitesofinﬂammationandservesasa
chemotactic agent for polymorphonuclear leucocytes
(Wolpe et al., 1989). CXCL3 is a potent neutrophil
chemoattractant both in vitro and in vivo, is up regulated
simultaneously with symptom onset of acute experimental
autoimmuneencephalomyelitis,theanimalmodelofMS,and
itsexpressioncorrelateswiththeintensityofinﬂammationin
the central nervous system (Glabinski et al., 1998). IL-8 is
AUTOIMMUNE MECHANISMS IN MULTIPLE SCLEROSIS 301FIGURE 1 Immunomodulatory treatment effect evaluated by gene expression. (A) Three dimensional scatter plot of 535 signiﬁcant genes ðp , 0:05Þ
demonstrating treatment effects in MS patients. y-axis denotes average fold change of each gene in non-treated patients, x-axis denotes average fold
change of each gene in treated patients, both in comparison with healthy subjects, z-axis denotes p-value by Info. Red color represents over-expressed
genes in untreated patients; blue color represents over-expressed genes in treated patients. (B) Proﬁles of abundant genes distinguishingtreatment effects
in MS patients during relapse. (C) Proﬁles of abundant genes distinguishing treatment effects in MS patients during remission.
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by severaltypesofcells in response to inﬂammatory stimuli.
SCYA2servesaschemotacticfactorthatattractsmonocytes,
binds to CCR2 and CCR4, and is implicated in the
pathogenesis of autoimmune diseases like psoriasis, and
rheumatoid arthritis. SCYA4 is a monokine with inﬂamma-
tory and chemokinetic properties that binds to CCR5 and to
CCR8 and was expressed both in the MS disease speciﬁc
signatureandintheimmunomodulatorytreatmentsignature,
suggesting a combined effect of this gene transcript.
SCYA20 is also a chemotactic factor for lymphocytes that
binds to CCR6.
T-cell Activation and Expansion
Thesecondmechanismtooperateisrelatedtoexpansionof
autoreactive T-cells, and involves several gene transcripts.
The interleukin family (IL1b, IL6, IL8, IL15) and
their receptors (IL1R1, IL11RA, IL2RB) have both
a pro-inﬂammatory and anti-inﬂammatory activities, and
are known to modulate the immune response and inﬂuence
autoimmuneactivity.IL2RBplaysaroleinT-cellmediated
immune response and is involved in receptor-mediated
endocytosis and transduces the mitogenic signals of IL2.
Its down-expression in the MS signature is in agreement
with the ﬁndings reported by Suzuki et al. (1995), that
demonstrated in IL2RB deﬁcient mice that IL2RB is
required to keep the activation program of T-cells under
control and prevent autoimmunity. Additionally, the
production of SCYA2 is regulated by IL2RB (Corrigall
et al.,2001). Another component of the interleukin family,
IL15, is known to stimulate the proliferation of
T-lymphocytes. Stimulation by IL15 requires interaction
ofIL15withcomponentsofIL2receptor,includingIL2RB
and possibly IL2RG. Another gene, NFATC3, also plays a
role in the inducible expression of cytokine genes in
response to antigenic stimulation of T-cells, especially in
response to IL2 induction.
TABLE I List of 30 cytokine-related gene transcripts in the MS speciﬁc signature
Gene identiﬁer TNOM p-value Info p-value t-test p-value Gene symbol Gene name
X52560 4.82E-03 4.47E-03 2.97E-04 CEBPB CCAAT/enhancer binding protein, beta
L06797 1.38E-03 4.99E-04 1.35E-03 CXCR4 Chemokine, receptor 4
AF046059 4.82E-03 4.02E-04 7.65E-04 CREME9 Cytokine receptor-like factor 3
U56998 1.38E-03 4.67E-05 6.69E-05 CNK Cytokine-inducible kinase
D86964 4.82E-03 4.16E-03 1.47E-04 DOCK2 Dedicator of cyto-kinesis 2
U43774 1.38E-03 1.96E-03 2.13E-04 FCAR Fc fragment of IgA, receptor
X54489 1.38E-03 5.88E-04 1.20E-03 GRO1 GRO1 oncogene
M36820 2.11E-06 1.80E-06 1.70E-07 GRO2 GRO2 oncogene
M36821 3.44E-04 4.67E-05 2.46E-06 GRO3 GRO3 oncogene
M94630 4.82E-03 1.61E-03 7.90E-04 HNRPD Heterogeneous nuclear ribonucleoprotein D
M27492 3.44E-04 7.05E-06 5.15E-06 IL1R1 Interleukin 1 receptor, type I
X04500 8.55E-11 8.55E-11 3.49E-12 IL1B Interleukin 1, beta
U32324 2.11E-06 4.08E-07 3.17E-08 IL11RA Interleukin 11 receptor, alpha
AF031167 1.38E-03 2.50E-03 2.15E-04 IL15 Interleukin 15
M26062 4.82E-03 4.16E-03 9.97E-04 IL2RB Interleukin 2 receptor, beta
X04430 7.44E-05 1.29E-04 4.21E-06 IL6 Interleukin 6 (interferon, beta 2)
M17017 3.44E-04 5.23E-05 3.08E-06 IL8 Interleukin 8
AB000734 1.37E-05 1.28E-06 2.07E-07 SSI-1 JAK binding protein
L36719 7.44E-05 7.05E-06 9.02E-07 MAP2K3 Mitogen-activated protein kinase kinase 3
L41067 1.38E-03 2.21E-03 1.54E-04 NFATC3 Nuclear factor of activated T-cells
U02020 1.38E-03 1.96E-03 4.96E-05 PBEF Pre-B-cell colony-enhancing factor
AB014519 1.38E-03 1.35E-03 4.99E-04 ROCK2 Rho-associated, coiled-coil protein kinase 2
M26683 4.82E-03 1.35E-03 1.25E-03 SCYA2 Small inducible cytokine A2
J04130 7.44E-05 4.67E-05 5.86E-06 SCYA4 SCYA4
U64197 8.55E-11 8.55E-11 6.81E-11 SCYA20 Small inducible cytokine subfamily A, 20
U10117 1.37E-05 5.01E-06 1.91E-07 SCYE1 Small inducible cytokine subfamily E, 1
AB004904 3.44E-04 1.90E-04 8.35E-04 SSI-3 STAT induced inhibitor 3
D38122 4.82E-03 4.16E-03 8.10E-05 TNFSF6 Tumor necrosis factor superfamily, member 6
S76792 1.37E-05 2.58E-05 4.27E-05 TNFRSF4 Tumor necrosis factor receptor superfamily, 4
X02910 7.44E-05 1.19E-05 2.20E-07 TNF Tumor necrosis factor, 2
TABLE II List of seven cytokine-related gene transcripts in the MS treatment signature
Gene identiﬁer TNOM p-value Info p-value t-test p-value Gene symbol Gene name
L22342 2.87E-03 4.47E-03 2.57E-03 IFI41 Interferon-induced protein 41
J04130* 1.26E-02 1.50E-02 6.30E-02 SCYA4 SCYA4
D11086 4.43E-02 1.17E-02 3.40E-02 IL2RG Interleukin 2 receptor, gamma
X63717 4.43E-02 1.17E-02 3.95E-02 TNFRSF6 Tumor necrosis factor receptor superfamily, 6
AI263885 4.43E-02 1.17E-02 1.34E-02 WSX-1 Class I cytokine receptor
L33404 4.43E-02 4.46E-02 7.02E-02 KLK7 Kallikrein 7
U43774* 4.43E-02 2.75E-02 7.51E-03 FCAR Fc fragment of IgA, receptor
*Gene transcripts common to both MS disease related signature and MS immunomodulatory treatment signature.
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A breakdown in apoptosis related signaling mechanisms
could result in the development of autoimmune disorders.
Accumulating data indicate that impaired apoptosis plays a
major role in the pathogenesis of MS. The group of TNF
family related genes (TNF, TNFSF6, TNFRSF4) has
multifunctional immune activities. TNFSF6 is a cytokine
and an apoptotic factor that binds to FAS antigen
and transduces the apoptotic signal into cells. It serves as a
costimulatory molecule during T-cell activation, is involved
in cytotoxic T-cell mediated apoptosis and in T-cells
development (Embree-Ku et al., 2002; Bolstad et al.,2 0 0 3 ;
Linkermann et al., 2003). Through FAS-antigen mediated
apoptosis TNFSF6 may have a role in the induction of
peripheral tolerance or induction of antigen stimulated
suicide of mature T-cells. Its under-expression in the MS
signature suggests impairment in immune tolerance and
apoptosis that lead to persistent autoimmune activity. TNF
was described as reducing the severity of prototypic Th1
diseasesincludingEAE,andasinhibitingTCRsignalingand
promoting Th2 cytokine production (O’Shea et al.,2 0 0 2 ) .
Itwasrecentlyreportedthattreatmentwithinterferonbetain
MS patients resulted in up-regulation of TNF inducing
ligand(Wandingeretal.,2003),thusitcouldbeimportantto
apoptotic associated pathways in MS.
Demyelination
Another important mechanism that is disturbed in MS is
related to remyelination and recovery. IL1b, previously
reported to promote remyelination in a model of massive
demyelination in mice, and IL1b
2/2 mice failed to
remyelinate properly (Mason et al., 2001). Its down
expression within the MS signature suggests impaired
remyelination that could be corrected by immunomodu-
latory treatment. Recently, it was suggested that IL-1RA
and IL-1b are markers for MS severity and that a speciﬁc
IL-1RA/IL-1b ratio was associated with worse prognosis
of the disease (Schrijver et al., 1999).
Immune Regulation
CEBPB is an important transcriptional activator in the
regulation of genes involved in immune and inﬂammatory
responses. It speciﬁcally binds to an IL1 response element
in the IL6 gene and might inﬂuence regulation of immune
response both in the periphery and in the central nervous
system. IL6 is an immunoregulatory cytokine. It was
demonstrated that the failure of IL6-deﬁcient mice to
overcome regulatory T-cell-mediated suppression resulted
in increased susceptibility to infection and resistance to
autoimmunity (Pasare and Medzhitov, 2003). Similarly, in
our study down expression of IL6 suggests impairment
in immune regulation that might enhance the autoimmune
process and epitope spreading in MS.
To summarize, we conclude that cytokine-associated
genes are involved in different immune mechanisms
whereby, autoreactive T-cells not normally deleted or
destroyed can propagate and lead to active demyelination
in MS. Future studies using gene microarray could be used
to examineMS related mechanisms as well as the action of
immunomodulatory treatments to optimize treatment
responses and to better understand the disease process.
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